Reported side effects are typically mild and transient: BPC-157: Nausea (rare), mild fatigue in the first week, minor injection site redness TB-500: Mild lethargy during the loading phase, transient head rush immediately after injection, injection site discomfort Combined stack: No documented synergistic toxicity in preclinical or clinical observational data The more significant risks relate to sourcing and administration rather than the peptides themselves
50% for vitamin C and 40% for tretinoin), without the irritation or photosensitivity that retinoids commonly cause
July 23, 2026: Pharmacy Compounding Advisory Committee meeting The FDA has scheduled a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23, 2026 to evaluate BPC-157 and TB-500 (free base and acetate forms), along with KPV and MOTs-C
Dosage: 1000 mcg per week (split into 2-3 doses) via subcutaneous injection
Our nurses will tell you exactly what to expect based on your situation, including how this formula compares to our other injectable and IV options
Storage of reconstituted peptides requires refrigeration at 2-8C to maintain stability
